Cargando…
MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models
The transcription factor CEBPA is a master regulator of liver homeostasis, myeloid cell differentiation and is downregulated in several oncogenic diseases. MTL-CEBPA is a small activating RNA drug which upregulates gene expression of CEBPA for treatment of hepatocellular carcinoma (HCC). We investig...
Autores principales: | Huang, Kai-Wen, Tan, Choon Ping, Reebye, Vikash, Chee, Cheng Ean, Zacharoulis, Dimitris, Habib, Robert, Blakey, David C., Rossi, John J., Habib, Nagy, Sodergren, Mikael H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431011/ https://www.ncbi.nlm.nih.gov/pubmed/34502076 http://dx.doi.org/10.3390/ijms22179168 |
Ejemplares similares
-
Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice
por: Zhou, Jiehua, et al.
Publicado: (2019) -
Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma
por: Setten, Ryan L., et al.
Publicado: (2018) -
Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer
por: Voutila, Jon, et al.
Publicado: (2017) -
Gene activation of CEBPA using saRNA: Preclinical studies of the first in human saRNA drug candidate for liver cancer
por: Reebye, Vikash, et al.
Publicado: (2018) -
Cannabinoids in the landscape of cancer
por: Mangal, Nagina, et al.
Publicado: (2021)